THU0179 Mir-382–5p targeting il-33 gene as biomarker to predict subclinical atherosclerosis progression in patients with early rheumatoid arthritis

• Published in: Annals of the rheumatic diseases Vol. 77; no. Suppl 2; p. 308
• Main Authors: Cheng, T.H., Shang, Q., Li, E. K. M., Li, M., Mak, W.Y., Kwok, K.Y., Yim, I.C.W., Wong, P.C.H., Lao, V.W.N., Pang, S.H.T., Kun, E.W.L., Tam, L.S.
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Limited 01.06.2018
• Subjects: Arteriosclerosis; Atherosclerosis; Biomarkers; Cardiovascular diseases; Chromosome 5; Gene expression; Health risk assessment; Hip; Interleukin 1; Low density lipoprotein; Metabolic disorders; miRNA; Pain; Patients; Rheumatoid arthritis; Risk assessment; Ultrasound
• ISSN: 0003-4967; 1468-2060
• DOI: 10.1136/annrheumdis-2018-eular.2395

BackgroundPatients with rheumatoid arthritis(RA) had increased risk of cardiovascular disease(CVD). IL-33, a member of the IL-1 family, plays an important role in the pathogenesis of RA and development of CVD. Yet, plasma IL-33 level was not detectable in most subjects which limits it’s utility as a biomarker for CVD. Meanwhile, microRNAs(miRNAs) targeting IL-33 gene expression might play a role.ObjectivesTo ascertain if dysregulated miRNAs targeting IL-33 gene expression in earlyRA patients were associated with subclinical atherosclerosis progressionMethods73 ERA patients were recruited for this 1 year cohort study. Potential miRNAs binding to IL-33 gene were predicted by miRanda. 10 miRNAs with the highest possibility of targeting functional sites of IL-33 gene were quantified in cell free plasma samples. cel-miR-39 was used as spike-in control. Carotid plaque(CP) was identified using high-resolution ultrasound annually. Plaque progression(PP) was defined as an increased region harbouring plaque.ResultsCPs were identified in 25 (34%) and 31 (43%) subjects at baseline and month 12 respectively. 16 (22%) subject had plaque progression(PP +group). At baseline, subjects in PP +group were older, with lower pain and patient global scores, a higher proportion on conventional synthetic DMARDs, and higher cardiovascular risk compared to patients without plaque progression (PP-) (table 1). Plasma level of miR-382–5 p in the PP +group was significantly higher than that in the PP- group after adjusting for baseline difference (table 1). Using multivariate logistic regression, miRNA-382–5 p was an independent predictor for plaque progression(OR:2.534, 95%CI=1.079–5.952, p=0.033) after adjustment of baseline characteristics. [AUC:0.66,95% CI:0.51–0.81,p=0.048]. Other independent predictor included higher baseline Framingham risk score, diastolic BP and lower pain score.Abstract THU0179 – Table 1Characteristics of patients with and without plaque progressionNo plaque progression (n=57)Plaque progression (n=16)pp* Age50±1256±70.011Gender, male11 (19.3%)6 (37.5%)0.128Franmingham Risk Score6.1±7.914.2±11.60.017log miRNAmiR_9_5 p−1.14±1.48−1.23±0.970.8250.947miR_382_5 p0.79±0.661.38±1.290.0940.011miR_377_3 p0.75±0.650.96±0.850.2850.783miR_590_3 p0.2±0.460.13±0.160.5170.472miR_499a_5 p−1.65±0.67−1.48±0.880.4180.370miR_145_5 p2.43±1.353.26±2.080.0600.169miR_542_3 p−1.95±0.55−1.85±0.990.6150.750miR_186_5 p2.67±1.422.77±1.690.8110.556miR_214_3 p−0.68±1.29−0.8±1.020.7300.849miR_496−1.65±0.9−1.68±0.830.9170.538*adjusted for age, sex, baseline NRS pain, patient global score, wrist to hip ratio, plasma LDL level and Frimingham risk scoreAbstract THU0179 – Figure 1Multivariate regression analysis for plaque progressionConclusionsmiR-382–5 p was an independent predictor for progression of subclinical atherosclerosis and may serve as a novel biomarker for cardiovascular risk assessment in ERA patients.AcknowledgementsAcknowledgement to Hong Kong Society of Rheumatology Project Fund for supporting this project.Disclosure of InterestNone declared